Sobi - Public Comps and Valuation Multiples

Sobi Overview

About Sobi

Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).

Founded

2001

HQ

Employees

1.9K+

Website

sobi.com

Sectors

Biopharmaceuticals
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $3.0B

LTM EBITDA $1.1B

EV

$13.8B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Sobi Financials

As of November 2025, Sobi reported last 12-month revenue of $3.0B and EBITDA of $1.1B.

In the same period, Sobi generated $2.3B in LTM gross profit and $231M in net income.

See Sobi valuation multiples based on analyst estimates

Sobi P&L

In the most recent fiscal year, Sobi reported revenue of $2.8B and EBITDA of $987M.

Sobi expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Sobi valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$3.0B	XXX	$2.8B	XXX	XXX	XXX
Gross Profit	$2.3B	XXX	$2.1B	XXX	XXX	XXX
Gross Margin	78%	XXX	78%	XXX	XXX	XXX
EBITDA	$1.1B	XXX	$987M	XXX	XXX	XXX
EBITDA Margin	38%	XXX	36%	XXX	XXX	XXX
EBIT	$548M	XXX	$595M	XXX	XXX	XXX
EBIT Margin	18%	XXX	22%	XXX	XXX	XXX
Net Profit	$231M	XXX	$411M	XXX	XXX	XXX
Net Margin	8%	XXX	15%	XXX	XXX	XXX
Net Debt	XXX	XXX	$1.6B	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Sobi including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $3.0B. EBITDA for the last twelve months was $1.1B. In the most recent fiscal year, Sobi achieved $2.8B in revenue and $987M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$3.0B	Analyst estimates available to subscribers	$2.8B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$2.3B	Analyst estimates available to subscribers	$2.1B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	78.4% gross margin	Analyst estimates available to subscribers	77.8% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$1.1B	Analyst estimates available to subscribers	$987M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	38.5% EBITDA margin	Analyst estimates available to subscribers	35.8% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$548M	Analyst estimates available to subscribers	$595M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	18.3% EBIT margin	Analyst estimates available to subscribers	21.6% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$231M	Analyst estimates available to subscribers	$411M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	7.7% net profit margin	Analyst estimates available to subscribers	14.9% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$1.6B	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Sobi

This financial data table provides comprehensive performance metrics for Sobi, a company based in Sweden. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Sobi generated $3.0B in revenue over the last twelve months.
The company achieved $1.1B in EBITDA over the last twelve months.
Gross profit for the last twelve months was $2.3B.
Net income over the last twelve months reached $231M.

Fiscal Year Performance

In the most recent fiscal year, Sobi reported $2.8B in total revenue.
Fiscal year EBITDA was $987M.
The company maintained a gross profit margin of 77.8% in the most recent fiscal year.
EBITDA margin for the fiscal year was 35.8%.
Net profit margin reached 14.9% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Sobi. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Sobi Stock Performance

Sobi has current market cap of SEK 118B (or $12.4B), and EV of SEK 130B (or $13.8B).

Market Cap Evolution

Sobi Stock Data

As of December 3, 2025, Sobi's stock price is SEK 341 (or $36).

See Sobi trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$13.8B	$12.4B	XXX	XXX	XXX	XXX	$0.66

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Sobi Valuation Multiples

Sobi's trades at 5.0x EV/Revenue multiple, and 13.9x EV/EBITDA.

See valuation multiples for Sobi and 15K+ public comps

Sobi Financial Valuation Multiples

As of December 3, 2025, Sobi has market cap of $12.4B and EV of $13.8B.

Equity research analysts estimate Sobi's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Sobi has a P/E ratio of 53.9x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$12.4B	XXX	$12.4B	XXX	XXX	XXX
EV (current)	$13.8B	XXX	$13.8B	XXX	XXX	XXX
EV/Revenue	4.6x	XXX	5.0x	XXX	XXX	XXX
EV/EBITDA	12.0x	XXX	13.9x	XXX	XXX	XXX
EV/EBIT	25.1x	XXX	23.2x	XXX	XXX	XXX
EV/Gross Profit	5.9x	XXX	n/a	XXX	XXX	XXX
P/E	53.9x	XXX	30.3x	XXX	XXX	XXX
EV/FCF	19.4x	XXX	29.7x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Sobi Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Sobi Margins & Growth Rates

Sobi's last 12 month revenue growth is 12%

Sobi's revenue per employee in the last FY averaged $1.5M, while opex per employee averaged $0.8M for the same period.

Sobi's rule of 40 is 44% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Sobi's rule of X is 67% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Sobi and other 15K+ public comps

Sobi Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	12%	XXX	10%	XXX	XXX	XXX
EBITDA Margin	38%	XXX	36%	XXX	XXX	XXX
EBITDA Growth	12%	XXX	23%	XXX	XXX	XXX
Rule of 40	44%	XXX	47%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	67%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$1.5M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.8M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	14%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	56%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial